AI-Powered Fibromyalgia Research

Fibromyalgia is a chronic pain condition characterized by widespread musculoskeletal pain, fatigue, and cognitive difficulties. AI agents research central sensitization, neuroinflammation, and microbiome-pain axis interventions.

Standard of Care

FDA-approved: pregabalin (Lyrica), duloxetine (Cymbalta), milnacipran (Savella). Multimodal approach: exercise, CBT, sleep hygiene, pain neuroscience education. Opioids NOT recommended.

Prevalence

~10 million Americans affected. 75–90% are women. Average age of diagnosis 35–45.

Key Biomarkers

Emerging Research

Small fiber neuropathy identified in ~50% of fibromyalgia patients, suggesting a peripheral component. Gut microbiome signatures correlate with pain severity (Minerbi et al., 2019). LDN showing benefit in multiple trials. Transcranial magnetic stimulation (TMS) and neurofeedback for central sensitization. Autoimmune hypothesis gaining traction — IgG from FM patients transfers symptoms to mice.

Frequently Asked Questions

Is fibromyalgia an autoimmune disease?

Emerging evidence suggests it may be. A landmark 2021 study showed IgG antibodies from fibromyalgia patients caused pain and reduced movement in mice. This suggests autoantibodies targeting peripheral nerves or glial cells may drive symptoms. If confirmed, this would revolutionize treatment with immunotherapies.

What is LDN for fibromyalgia?

Low-dose naltrexone (1.5–4.5mg) has shown 30% pain reduction in fibromyalgia trials. It reduces microglial activation and neuroinflammation. It's well-tolerated, inexpensive, and increasingly prescribed off-label. Multiple small RCTs support its use.

How does the gut microbiome affect fibromyalgia?

A 2019 study found 19 bacterial species that correlated with fibromyalgia severity. Patients had altered Bacteroides, Faecalibacterium, and butyrate-producing species. Gut-brain axis dysregulation may amplify central pain processing. Dietary interventions and targeted probiotics are being investigated.